BioLife Solutions Competitors
| BLFS Stock | USD 18.85 -0.68 -3.48% |
Correlation: BioLife Solutions vs Establishment Labs Overview
Modest diversification
The correlation between BLFS and ESTA is 0.28, which Macroaxis classifies as Modest diversification for the selected horizon. Used correctly, the chart supports evaluation of whether adding the second position genuinely diversifies the first.
Moving together with BioLife Stock
Moving against BioLife Stock
Mean reversion in BioLife Solutions' price occurs when temporary dislocations - caused by sentiment extremes, news events, or liquidity shocks - correct back toward the stock's historical fair value.
BioLife Solutions Competition Correlation Matrix
Studying peer correlation around BioLife Solutions gives investors a cleaner read on how much independent price behavior still exists across the competitive set. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
BioLife Solutions Company may look attractive on headline returns alone, but deeper analysis often tells a different story. A thorough review of BioLife Solutions' risk-adjusted indicators provides a clearer picture of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KMTS | 2.65 | -0.30 | 0.00 | -0.42 | 0.00 | 4.70 | 20.42 | |||
| NVCR | 3.27 | 0.14 | 0.02 | 0.00 | 4.19 | 6.04 | 36.05 | |||
| AZTA | 2.30 | -0.64 | 0.00 | -0.59 | 0.00 | 3.76 | 29.88 | |||
| STAA | 2.39 | -0.46 | 0.00 | 3.19 | 0.00 | 4.66 | 14.47 | |||
| PHR | 1.92 | -0.38 | 0.00 | -0.45 | 0.00 | 3.97 | 12.98 | |||
| PLSE | 3.89 | 1.27 | 0.21 | 0.23 | 3.76 | 7.62 | 66.16 | |||
| NEOG | 2.11 | 0.59 | 0.19 | 0.25 | 2.20 | 3.71 | 40.83 | |||
| HROW | 2.73 | -0.17 | 0.00 | -0.16 | 0.00 | 5.98 | 37.75 | |||
| ATRC | 2.03 | -0.45 | 0.00 | -0.53 | 0.00 | 2.67 | 24.05 | |||
| ESTA | 2.33 | -0.03 | 0.00 | -0.11 | 0.00 | 4.55 | 13.50 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in BioLife Solutions financial statement analysis. It represents the amount of money remaining after all of BioLife Solutions operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare BioLife Solutions and related stocks such as Kestra Medical, Novocure, and Azenta Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KMTS | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -29.5 M | -34.1 M | -84.2 M | -84.2 M | -94.1 M | -113.8 M | -102.4 M | -107.6 M |
| NVCR | -77.4 M | -77.4 M | -77.4 M | -77.4 M | -80.7 M | -111.6 M | -131.8 M | -61.7 M | -63.6 M | -7.2 M | 19.8 M | -58.4 M | -92.5 M | -207 M | -168.6 M | -136.2 M | -143 M |
| AZTA | 1.5 M | 136.8 M | -2.2 M | 4.5 M | 14.2 M | -69.5 M | 62.6 M | 116.6 M | 28.8 M | 64.9 M | 110.7 M | -429 M | -14.3 M | -164.9 M | -55.8 M | -64.1 M | -67.3 M |
| STAA | -3.8 M | 1.3 M | -1.8 M | 398 K | -8.4 M | -6.5 M | -12.1 M | -2.1 M | 5 M | 14 M | 5.9 M | 27.5 M | 39.7 M | 21.3 M | -20.2 M | -80.4 M | -76.4 M |
| PHR | -18.2 M | -18.2 M | -18.2 M | -18.2 M | -18.2 M | -18.2 M | -18.2 M | -18.2 M | -15.1 M | -20.3 M | -27.3 M | -118.2 M | -176.1 M | -136.9 M | -58.5 M | -52.7 M | -55.3 M |
| PLSE | -474.9 K | -474.9 K | -474.9 K | -474.9 K | -474.9 K | -2.8 M | -9.5 M | -25.6 M | -37.5 M | -46 M | -49.7 M | -63.2 M | -59 M | -42.2 M | -53.6 M | -72.8 M | -69.1 M |
| NEOG | -1.1 M | 22.5 M | 27.2 M | 28.2 M | 33.5 M | 36.6 M | 43.8 M | 63.1 M | 60.2 M | 59.5 M | 60.9 M | 48.3 M | -22.9 M | -9.4 M | -1.1 B | -982.8 M | -933.7 M |
| HROW | -46.2 K | -954 K | -5.4 M | -7.6 M | -10.1 M | -15.9 M | -19.1 M | -12 M | 14.6 M | 168 K | -3.4 M | -18 M | -14.1 M | -24.4 M | -17.5 M | -5.1 M | -5.4 M |
| ATRC | -3.6 M | -5.5 M | -7.5 M | -11.5 M | -16.2 M | -27.2 M | -33.3 M | -26.9 M | -21.1 M | -35.2 M | -48.2 M | 50.2 M | -46.5 M | -30.4 M | -44.7 M | -11.4 M | -12 M |
| ESTA | -1.6 M | -1.6 M | -1.6 M | -1.6 M | -1.6 M | -1.6 M | -22.2 M | -34.9 M | -21.1 M | -38.1 M | -38.1 M | -41.1 M | -75.2 M | -78.5 M | -84.6 M | -51.1 M | -53.6 M |
BioLife Solutions Competitive Analysis
To gauge BioLife Solutions' financial strength, comparing it with Kestra Medical, Novocure, and Azenta offers useful context. BioLife Solutions is valued at 923.5 M and generates 96.2 M in revenue. With a -3.37% return on equity and -4.78% net margin, BioLife Solutions faces a more difficult earnings environment than some peers. On equity returns, BioLife Solutions earns -3.37% compared to -126.40% at Kestra Medical. Revenue tilts toward Novocure at 655.4 M compared with 96.2 M. BioLife Solutions keeps more of each revenue dollar with a -4.78% margin versus -10.12% at Azenta.| Better Than Average | Worse Than Peers | View Performance Chart |
BioLife Solutions Competition Peer Performance Charts
How to Analyze BioLife Solutions Against Peers
BioLife Solutions' peer analysis compares BioLife Solutions with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether BioLife Solutions trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where BioLife Solutions leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Revenue growth ranking for BioLife Solutions within its peer group shows whether it is gaining or losing competitive position over time. The four dimensions that most reliably separate industry leaders from laggards are valuation, profitability, leverage, and growth rate for BioLife Solutions. Comparing small-cap peers in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care can help separate structural strengths from temporary momentum. For peer comparison, BioLife Solutions has a market cap of 923.5 M, P/E of 173.59, profit margin of -4.78%.
This section for BioLife Solutions is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Analyst projections are included when active coverage applies. Values may update on different source schedules.